The test is designed to detect the presence or absence of the Zika virus in serum or plasma collected alongside urine from patients with suspected infection.
The partnership will enable the design, development, and manufacture of a test to rapidly detect dengue, Chikungunya, and Zika viruses.
Participants at the Next Generation Dx Summit last week noted that POC testing could prove vital in diagnosing and containing highly infectious diseases.
The test can be used on donated blood samples as well as other human cells and tissues.
The FDA said that pooled testing of donations using a screening test that it has licensed is a sufficient method for complying with its testing regulations.
The initial focus will be on Zika and chikingunya, and will leverage iBio's antigen and antibody manufacturing capabilities for product prototype development.
They have begun field testing near-infrared spectroscopy as an alternative to PCR and ELISA for routine pathogen screening in mosquitoes.
The tests are based on Chembio's Dual Path Platform chromatographic immunoassay technology, which can detect antibodies within 15 minutes using fingerstick samples.
The claim, enabling streamlined screening of pooled samples, follows updated industry recommendations for Zika virus screening in the US blood supply.
Despite the astronomical costs, it may prove challenging to reverse course and discontinue Zika testing according to a commentary article accompanying a NEJM study.